Autoimmune-Induced Alopecia and Emerging Therapies in Hair Loss

Dear Colleagues,

Autoimmune-induced alopecia, such as alopecia areata and cicatricial alopecia, occurs when the immune system mistakenly attacks hair follicles, leading to hair loss. Recent advances in treatment have focused on emerging therapies that aim to modulate immune responses and promote follicular regeneration and hair growth, spanning from medical therapies to surgical options.

The aim of this Special Issue is to review the pathophysiological mechanisms behind hair loss and to evaluate the efficacy and safety of emerging therapies in the management of this condition. It seeks to provide a comprehensive scope that includes patient management strategies and future directions in research and therapy.

Autoimmune-induced alopecia primarily includes alopecia areata, which itself can manifest in several forms such as patchy alopecia areata, where hair falls out in small patches, and alopecia totalis and universalis, where complete loss of hair occurs on the scalp or all over the body, respectively. Another type, scarring alopecia, involves the destruction of hair follicles and replacement with scar tissue, permanently impacting hair growth. Novel hair treatments have revolutionized patient management in dermatology by providing truly effective therapies. These advancements have not only improved clinical outcomes, with higher rates of hair regrowth, but have also enhanced the quality of life for patients by offering treatments with fewer side effects and better disease control.

This Special Issue spotlights novel insights into immunological underpinnings and genetic predispositions of autoimmune-induced alopecia. It also explores emerging therapies in hair loss, including new pharmacological interventions, gene therapy techniques and biotechnological advances, aiming to revolutionize treatment paradigms and patient outcomes in hair loss management.

We encourage the submission of papers focused on autoimmune-induced alopecia and new therapeutic options for any type of hair loss, including medical therapies and surgical approaches.

Dr. David Saceda-Corralo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• autoimmune-induced alopecia
• alopecia areata
• cicatricial alopecia
• occurs
• hair loss